Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Street Poller Media and The Boom of the Street Interview Ad Industry 
France Targets Shein, Temu With Fast-Fashion Fees 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Shein Shares Slide 9% in Hong Kong IPO Debut 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Faraday Future Delivers First Robots in Middle East, Plans September Launches 
OpenAI Rejects Apple Trade Secret Theft Claims 
The Realist’s Case: Lukas Kerrebijn of RD Dubai on the Narrative Dubai’s Agents Won’t Question 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Amazon Secures 200 MW Wind Power Deals in Sweden 
Add as a preferred source on Google
MENLO PARK, Calif., March 20, 2018 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the 17th Annual Needham Healthcare Conference.
- Location: New York, NY
- Presentation date: Tuesday, March 27, 2018
- Presentation time: 9:30 a.m. ET
A live audio webcast and archive of the presentation will be available at http://investor.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s pipeline includes two late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), for which a New Drug Application is under review by the U.S. Food and Drug Administration for the treatment of primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed for normal body temperature regulation), and lebrikizumab, in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com. Follow @DermiraInc on Twitter and LinkedIn.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com), LinkedIn page (https://www.linkedin.com/company/dermira-inc) and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website, LinkedIn page and Twitter account in addition to following its SEC filings, press releases, public conference calls and webcasts.
Contacts:
Media:
Erica Jefferson
Vice President, Corporate Communications
650-421-7216
[email protected]
Investors:
Ian Clements, Ph.D.
Vice President, Investor Relations
650-422-7753
[email protected]
Robert H. Uhl
Westwicke Partners
Managing Director
858-356-5932
[email protected]
